U.S. Markets open in 1 hr 23 mins

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.69-0.07 (-1.04%)
At close: 4:00PM EST

Aldeyra Therapeutics, Inc.

131 Hartwell Avenue
Suite 320
Lexington, MA 02421
United States
781 761 4904

Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Dr. Todd C. Brady M.D., Ph.D.CEO, Pres & Director769.55kN/A1972
Mr. Joshua Reed M.B.A.Chief Financial Officer583.49kN/A1973
Dr. David J. ClarkConsultant584.2kN/A1965
Dr. Stephen G. MachathaSr. VP of Technical OperationsN/AN/A1977
Ms. Mary Taylor M.P.H.Sr. VP of Regulatory AffairsN/AN/A1959
Mr. David B. McMullin M.B.A.Chief Bus. OfficerN/AN/A1975
Dr. James A. Gow M.D.Sr. VP of Clinical Devel.N/AN/A1967
Mr. Bruce Greenberg CPA, M.B.A.VP & ControllerN/AN/AN/A
Adam BrockmanDirector of Toxicology & PharmacologyN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, a sight-threatening retinal disease. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Aldeyra Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.